The chronic administration of ethionine, an analogue of methionine and alkylating hepatocarcinogen, to rats resulted in the decrease of hepatic drug metabolizing enzyme activities and cytochrome P-450 content. In contrast, the activity of hepatic heme oxygenase, a first enzyme of heme degradative pathway, was increased following ethionine administration. delta-Aminolevulinic acid (ALA) synthetase, a key enzyme of heme biosynthesis pathway, was also increased except during 9 to 15 weeks of the experimental period. Changes of cytochrome P-450 content and heme oxygenase activity were proportional to the carcinogen provided period. Further, ethionine induced neoplastic nodules showed more profound changes in heme oxygenase, ALA synthetase and drug metabolizing enzyme activities than the surrounding liver. Similar changes in the enzyme activities were also obtained by a single administration of ethionine to rats and these effects were dependent upon dose levels of the carcinogen except ALA synthetase activity. These results revealed that ethionine is a mild inducer of hepatic heme oxygenase. It is thus likely that induction of heme oxygenase produced by ethionine could lead to the decrease of cytochrome P-450 and drug metabolizing enzyme activities in the liver. The decrease of heme availability due to induction of heme oxygenase by ethionine may be one of the explanations for the decrease of cytochrome P-450 content under the experimental conditions.